Cervarix 'gets better immunse response' than Gardasil
The results of the first head-to-head trial of the two cervical cancer vaccines has shown Cervarix, used in the national vaccination campaign, elicits a better immune response in women than Gardasil.
The trial of 1,110 US women aged 18-45 found Cervarix induced the production of 2.7 times more memory B cells – a key measure of immune response – than Gardasil for HPV types 16 and 18. Tolerability and safety results were similar for the two vaccines.
Dr Anne Szarewski, clinical consultant at the Wolfson Institute of Preventive Medicine said: ‘This study offers evidence for the first time that the two HPV vaccines do not generate the same level of response against the two most common cancer causing virus types.'
The results were presented at the International Papillomavirus Conference in Malmö, Sweden.
Cervarix: research found it generated better immune response to HPV than competitor Gardasil Cervarix: research found it generated better immune response to HPV than competitor Gardasil
